10 results match your criteria: "Northern Clinical Diagnostics and Thrombovascular Research[Affiliation]"
Blood Vessel Thromb Hemost
August 2025
Northern Clinical Diagnostics and Thrombovascular Research, Northern Health, Melbourne, VIC, Australia.
J Thromb Thrombolysis
September 2025
Department of Haematology, Northern Hospital, 185 Cooper St, Epping, VIC, 3076, Australia.
Iliofemoral deep vein thrombosis (IFDVT) is associated with potential for poor outcomes despite optimal anticoagulation therapy. To characterize the real-world management of IFDVT in an Australian population. Retrospective evaluation of IFDVT cases managed at Northern Health, Australia from January 2011 to December 2020 was performed and compared to non-iliofemoral lower limb DVTs (non-IFDVT) (n = 1793).
View Article and Find Full Text PDFRes Pract Thromb Haemost
July 2025
Department of Haematology, Tan Tock Seng Hospital, Singapore.
Background: Artificial Intelligence (AI) and machine learning (ML) are transforming hemostasis and thrombosis care, with applications spanning disease detection, risk assessment, laboratory testing, patient education, personalized medicine, and drug development. This narrative review explores AI's clinical utility and limitations across these 6 domains.
Methods: A comprehensive search of PubMed, Embase, and Scopus (up to February 2025) was conducted using terms related to AI, thrombosis, and hemostasis.
Semin Thromb Hemost
May 2025
Northern Clinical Diagnostics and Thrombovascular Research (NECTAR), Northern Health, Epping, Victoria, Australia.
Chronic kidney disease (CKD) affects over 10% of the global population and significantly increases the risk of cardiovascular disease as well as arising bleeding. There are alterations in hemostasis, which are multifactorial, involving complex interactions between coagulation, platelets, and the vessel wall. Hemostasis evaluation in CKD is critical for the optimal management of patients.
View Article and Find Full Text PDFJ Thromb Thrombolysis
March 2025
Northern Clinical Diagnostics and Thrombovascular Research (NECTAR), Northern Health, Melbourne, Australia.
Increased tissue factor pathway inhibitor (TFPI) has been associated with cardiovascular disease (CVD). We aim to evaluate the predictive capability of TFPI for atherothrombotic events (ATE) in patients with chronic kidney disease (CKD) and diabetes. A prospective observational study was performed at Northern Health, Australia.
View Article and Find Full Text PDFPLoS One
May 2025
Northern Clinical Diagnostics and Thrombovascular Research (NECTAR) Centre, Northern Health, Melbourne, Victoria, Australia.
Carrageenan-containing nasal sprays, available over-the-counter (OTC), are often marketed as having anti-viral effects. Carrageenan belongs to the glycosaminoglycan family alongside heparin, and heparin is known to inhibit real-time quantitative polymerase chain reaction (RT-qPCR) in nasopharyngeal swabs used to detect SARS-CoV-2. As heparin and carrageenan share structural similarities, this work aimed to investigate the interferent effect of carrageenan on RT-qPCR for SARS-CoV-2 detection across 4 different diagnostic platforms.
View Article and Find Full Text PDFCVIR Endovasc
February 2025
Interventional Radiology Service, Northern Health, Northern Imaging Victoria, Melbourne, Australia.
Background: Macroscopic fat pulmonary embolism is extremely uncommon. Most cases occur in the context of fat grafting or long bone fractures. Macroscopic fat pulmonary embolism may be associated with cardiopulmonary compromise and is associated with high mortality.
View Article and Find Full Text PDFJ Clin Med
October 2024
Department of Haematology, Northern Hospital, Epping, VIC 3076, Australia.
Upper extremity deep vein thrombosis (UEDVT) is uncommon but not insignificant. The current literature is limited, and the management is largely extrapolated from the treatment of lower extremity DVTs (LEDVT). : A retrospective review was conducted on patients diagnosed with UEDVT at Northern Health, Victoria, Australia, between December 2010 and December 2022.
View Article and Find Full Text PDFJ Virol Methods
June 2024
Northern Pathology Victoria, Northern Health, Epping, VIC, Australia; NorthErn Clinical diagnostics and ThrombovAscular Research (NECTAR) Centre, Northern Health, Epping, VIC, Australia; Department of Medicine - Northern Health, University of Melbourne, Epping, VIC, Australia.
Heparin is postulated to block the interaction of SARS-CoV-2 with highly glycosylated proteins which are critical for binding the angiotensin-converting enzyme 2 (ACE2), an essential mechanism for host-cell entry and viral replication. Intranasal heparin is under investigation for use as a SARS-CoV-2 preventative in the IntraNasal Heparin Trial (INHERIT, NCT05204550). Heparin directly interferes with real-time quantitative polymerase chain reaction (RT-qPCR), the gold standard for SARS-CoV-2 detection.
View Article and Find Full Text PDFJ Thromb Thrombolysis
April 2024
NorthErn Clinical Diagnostics and ThrombovAscular Research (NECTAR) Centre, Northern Health, 185 Cooper St, Epping, VIC, 3076, Australia.
DOACs have emerged as first-line treatment in most cancer-associated thrombosis (CAT), representing a paradigm shift in its management. However, CAT management remains challenging and requires careful risk-benefit considerations. A retrospective analysis of CAT presentations to a tertiary referral centre from January 2011 to December 2020.
View Article and Find Full Text PDF